The Efficacy of Corticosteroid Therapy in a Patient with Non-alcoholic Steatohepatitis Overlapping Autoimmune Hepatitis

Takuya Komura¹,², Hajime Ohta¹, Takuya Seike¹, Yoshiaki Shimizu¹, Ryotaro Nakai¹, Hitoshi Omura¹, Takashi Kagaya¹, Satomi Kasashima³, Atsuhiro Kawashima³, Saka Oba⁴, Kennichi Harada⁵, Shuichi Kaneko² and Masashi Unoura¹

Abstract:

The overlap of multiple liver diseases can cause the disease activity and severity to worsen rapidly in some cases. We rarely see patients with non-alcoholic steatohepatitis (NASH) with overlapping autoimmune hepatitis (AIH). A 64-year-old woman who had been prescribed oral drugs to treat diabetes and hypertension (metformin 500 mg/day and voglibose 0.9 mg/day, and termisartan 40 mg/day and amlodipine 5 mg/day, respectively) was diagnosed with NASH with histological confirmation. At 68 years of age, her liver injury worsened with an IgG of 2,871 mg/dL and a high serum anti-nuclear antibody (ANA) level of 2,560. We repeated the liver biopsy, which revealed NASH and mild interface hepatitis with some lobular focal necrosis consisting of overlapping AIH. Therefore, she was treated with 30 mg of prednisolone daily. The treatment led to an improvement in her IgG levels and ANA in the serum and an improvement in the histology results.

Key words: non-alcoholic steatohepatitis, autoimmune hepatitis, overlap

(Intern Med 57: 807-812, 2018)
(DOI: 10.2169/internalmedicine.8887-17)

Introduction

The increasing prevalence of non-alcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease (NAFLD), has recently become a major health concern worldwide (1). NAFLD/NASH is closely related to metabolic disorders such as hyperinsulinemia, diabetes, dyslipidemia, visceral adiposity, and hypertension, which are considered the hepatic phenotype of metabolic syndrome, with increased risks of morbidity and mortality related to cardiovascular diseases (2-4).

Chronic liver diseases are sometimes complicated with other liver diseases, such as hepatitis C overlapping NAFLD/NASH, which involves a more aggressive inflammatory condition and progressive stage (5). In addition, NAFLD/NASH can overlap autoimmune hepatitis (AIH) (6), and this has a reported worldwide prevalence of 1.8-3.6% (7) and a prevalence of 1.9% in Japan (8).

Anti-nuclear antibodies (ANAs), an essential diagnostic criterion for AIH, are positive in 20-33% of patients with NAFLD/NASH (7, 9). Consequently, ANA-positive women with NASH are sometimes misdiagnosed with AIH. Therefore, histological confirmation with a liver biopsy is critical for a definitive diagnosis of NASH overlapping AIH (10, 11). There are few reports on the role of a liver biopsy in developing a treatment strategy for NASH overlapping AIH. We herein report a case in which the histological confirmation of AIH led to remission with appropriate corticosteroid therapy in a deteriorating patient with NASH.

¹Department of Gastroenterology, National Hospital Organization Kanazawa Medical Center, Japan, ²System Biology, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Japan, ³Department of Clinical Laboratory, National Hospital Organization Kanazawa Medical Center, Japan, ⁴Saka Internal Medical Clinic, Japan and ⁵Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Japan

Received: January 21, 2017; Accepted: June 20, 2017; Advance Publication by J-STAGE: November 20, 2017
Correspondence to Dr. Takuya Komura, t.komura@m-kanazawa.jp
Case Report

A 64-year-old woman (height: 156 cm, body weight: 61.0 kg, body mass index: 25.1 kg/m²), who had been taking oral drugs to treat type 2 diabetes and hypertension, was diagnosed with liver injury based on blood tests. She had no other remarkable medical history, and there was no evidence of endocrine disease. She had no history of any digestive or gynecological surgeries. There was also no drinking history. Abdominal ultrasonography and computed tomography (CT) revealed fatty changes and the appearance of chronic liver disease with splenomegaly, but no ascites (Fig. 1). Various viral hepatitis markers, ANA, and anti-mitochondrial antibody were negative, and the serum immunoglobulin fraction was normal (Table 1). The liver biopsy showed mild interface hepatitis in the mild inflamed portal tracts in addition to steatohepatitis, including moderate steatosis (20%), some focal necrosis (Fig. 2a), perivenular/pericellular fibrosis (Fig. 2b), ballooning hepatocytes (Fig. 2c), and Mallory-Denk bodies (Fig. 2d). She was classified as Matteoni classification type 4 and Brunt classification grade 1 stage 4. Her NAFLD activity score (NAS) was 4 (steatosis 1; lobular inflammation 1; and hepatocyte ballooning 2). No hepatitis A, B, or C virus markers were detected. Her international AIH score increased to 18 points.

Consequently, the patient was diagnosed with advanced chronic liver disease caused by mainly NASH. Her treatment involved improved control of her diabetes and lifestyle follow-up.

| Table 1. Laboratoty Data at the First Time of Liver Biopsy. |
|---------------------------------------------------------------|
| WBC 6.9×10³ /mm³   | T-Bil 0.5 mg/dL   | IgG 1.608 mg/dL |
| Neu 55 %            | D-Bil 0.3 mg/dL   | IgA 479 mg/dL   |
| Eos 6.0 %           | ALP 428 IU/L      | IgM 182 mg/dL   |
| Baso 0 %            | γ-GTP 68 IU/L     | HA 92.4 ng/mL   |
| Lym 34 %            | AST 43 IU/L       | AFP 4.3 ng/mL   |
| Mono 5.0 %          | ALT 32 IU/L       | ANA x40 |
| RBC 4.1×10⁸ /mm³    | LDH 227 IU/L      | Anti-M2 Ab (-) |
| Hb 12.1 g/dL        | ZTT 12.1 U        | HBs-Ag (-)     |
| Ht 37.1 %           | TTT 7.3 U         | HBs-Ab (-)     |
| Plt 12.4×10⁴ /mm³   | TP 7.9 g/dL       | HCV-Ab (-)     |
| PT-INR 1.13         | T-chol 191 mg/dL  | FBS 135 mg/dL  |
| BUN 17.5 mg/dL      | HDL-C 50 mg/dL    | HbA1c 6.0 %    |
| Cre 0.63 mg/dL      | LDL-C 112 mg/dL   |                 |
|                    | TG 145 mg/dL      |                 |
|                    | UA 4.8 mg/dL      |                 |

HA: hyaluronic acid, Ab: anti-body, ANA: anti-nuclear antibody, FBS: fasting blood sugar, TG: triglyceride, UA: Uric acid

overlapping AIH.

Figure 1. Abdominal CT showing liver deformity and splenomegaly, indicating advanced chronic liver disease. No hepatocellular carcinoma or ascites was evident.
After about 4 years on this therapy, her liver function test results again worsened with an IgG of 2,871 mg/dL and a serum ANA titer of over 2,560 times the normal amount (Table 2). We repeated the liver biopsy, which revealed steatosis with moderate perivenular/pericellular fibrosis forming bridging (Fig. 3a, b), mild interface hepatitis (Fig. 3c) in the moderately inflamed portal tracts with several plasma cells (Fig. 3d), and hepatic rosettes (Fig. 3e) [Matteoni classification type 4; Brunt classification grade 2, stage 4; and NAS score of 4 (steatosis 1; lobular inflammation 1; and hepatocyte ballooning 2)]. Her international AIH score increased to 20 points. Since she was diagnosed with NASH overlapping AIH, oral corticosteroid therapy was initiated at 30 mg of prednisolone daily.

Table 2. Laboratory Data at the Second Time of Liver Biopsy.

| WBC         | 4.0×10³ /mm³ | T-Bil  | 1.0 mg/dL | IgG   | 2,871 mg/dL |
|-------------|--------------|--------|-----------|-------|-------------|
| Neu         | 59.1 %       | D-Bil  | 0.5 mg/dL | IgA   | 524 mg/dL   |
| Eos         | 3.5 %        | ALP    | 302 IU/L  | IgM   | 135 mg/dL   |
| Baso        | 0.5 %        | γ-GTP  | 99 IU/L   | HA    | 735 mg/mL   |
| Lym         | 28.8 %       | AST    | 114 IU/L  | AFP   | 6.8 mg/mL   |
| Mono        | 8.1 %        | ALT    | 58 IU/L   | ANA   | ×2,560 speckled pattern |
| RBC         | 4.0×10⁶ /mm³ | LDH    | 270 IU/L  |       |             |
| Hb          | 12.2 g/dL    | ZTT    | 16.0 U    | Anti-M2 Ab | (-)        |
| Ht          | 35.3 %       | TTT    | 23.0 U    | HBs-Ag | (-)        |
| Plt         | 8.5×10⁴ /mm³ | TP     | 7.8 g/dL  | HBs-Ab | (-)        |
| PT-INR      | 1.17         | Alb    | 3.9 g/dL  | HCV-Ab | (-)        |
| BUN         | 16.1 mg/dL   | T-Chol | 125 mg/dL | FBS   | 111 mg/dL   |
| Cre         | 0.64 mg/dL   | HDL-C  | 50 mg/dL  | HbA1c | 5.9 %      |
| LDL-C       | 32 mg/dL     |       |           |       |             |
| TG          | 114 mg/dL    |       |           |       |             |
| UA          | 6.4 mg/dL    |       |           |       |             |
| Ferritin    | 86.8 ng/dL   |       |           |       |             |

HA: hyaluronic acid, Ab: anti-body, ANA: anti-nuclear antibody, FBS: fasting blood sugar, TG: triglyceride, UA: Uric acid
Although the IgG level and ANA titer decreased, the liver function test results did not improve. Furthermore, we observed increases in her body weight and HbA1c level. We postulated that the NASH disease activity had worsened, while the AIH had improved. This was confirmed histologically with a liver biopsy after six months of corticosteroid therapy. The histology results showed an improvement in interface hepatitis and portal inflammation with several plasma cells.
cells, but steatosis was still observed (Fig. 4) [Matteoni classification type 4; Brunt classification grade 2, stage 4; and NAS score of 5 (steatosis 1; lobular inflammation 2; and hepatocyte ballooning 2)]. The CT results did not show a change in the extent of her fatty liver, although her liver fibrosis had progressed (Fig. 5). Her international AIH score decreased to 15 points. Therefore, we focused on improving the control of her diabetes with insulin therapy (Insulin lispro 16 Units, 16 Units, 16 Units) and lifestyle changes. These treatments led to not only an improvement in her diabetes and body weight but also an improvement in her liver function test results (Fig. 6).

**Discussion**

We reported a patient with NASH overlapping AIH with corticosteroid therapy, which led to improved focal necrosis and interface hepatitis confirmed histologically with an improvement in the serum IgG level and ANA titer, but the development of steatosis as the NASH worsened.

Although NASH occasionally overlaps AIH, it is difficult to diagnose the presence of overlapping AIH because the serum ANA titer is sometimes positive in NASH patients. It is very important to diagnose AIH because steroid therapy, which is the first-line therapy for AIH, often exacerbates NASH due to worsening of fatty liver and diabetes, as in our case. Although no criteria have been established for diagnosing NASH overlapping AIH, coexisting AIH has distinct histological features, such as interface hepatitis and rosette formation, in addition to the histological features of NASH (12). Our patient had more marked interface hepatitis in the portal area than is typical in NASH patients, with elevated serum IgG levels and ANA titer. The serum IgG concentration has been recognized as an essential marker for diagnosing and treating AIH. The improvement in the serum IgG concentration, interface hepatitis, and portal inflammation confirmed the presence of NASH overlapping AIH in our case. However, we can minimize the steroid-induced worsening of NASH by controlling patients’ body weight and metabolic abnormalities, such as diabetes, that often coexist with NASH (13). If the NASH is not under control because of steroid therapy, azathioprine or ursodeoxycholic

![Figure 5. Abdominal plain CT shows no changes in the extent of fatty liver, although her liver fibrosis progressed.](image)

![Figure 6. Summary of the clinical course.](image)
acid is recommended to control NASH overlapping AIH (8).

The liver is a central immune organ with high exposure to circulating antigens and endotoxins via the gut microbiota. It contains many innate immune cells, such as macrophages and innate lymphoid cells (14), and Toll-like receptor signaling or inflammasome activation initiates inflammatory responses in the liver. Innate immune activation plays a crucial role in triggering and the progression of hepatic inflammation, injury, and fibrosis in NASH (15, 16), as in AIH (17). Therefore, further studies are needed to clarify the common points and differences in the host immune response in NASH overlapping AIH in order to establish a treatment strategy and elucidate the disease state.

In conclusion, histological confirmation is useful for determining the disease status and selecting a therapeutic strategy in patients with NASH overlapping with AIH. Steroid therapy is necessary to treat the condition when the presence of focal necrosis is confirmed through a liver biopsy. However, we must be careful, as steroid therapy can worsen NASH.

The authors state that they have no Conflict of Interest (COI).

References

1. Masarone M, Federico A, Abenavoli L, et al. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 9: 126-133, 2014.
2. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10: 330-344, 2013.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023, 2012.
4. Francque S, Laleman W, Verbeke L, et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest 92: 1428-1439, 2012.
5. Adinolfi LE, Rinaldi L, Guerrera B, et al. NAFLD and NASH in HCV infection: prevalence and significance in hepatic and extrahepatic manifestations. Int J Mol Sci 17: 803-809, 2016.
6. Loria P, Carulli N, Lonardo A. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 100: 1200-1202, 2005.
7. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 99: 1316-1320, 2004.
8. Yatsuji S, Hashimoto E, Kaneda H, et al. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? J Gastroenterol 40: 1130-1138, 2005.
9. Loria P, Lonardo A, Leonardi F, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 48: 2173-2181, 2003.
10. Targher G, Bertolini L, Rodella S, et al. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol 64: 337-341, 2006.
11. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023, 2012.
12. Niwa H, Sasaki M, Haratake J, et al. Clinico-pathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol Res 37: 923-931, 2007.
13. Fukuda S, Komori A, Itoh M, Mihara Y, et al. Histological remission during corticosteroid therapy of overlapping nonalcoholic steatohepatitis and autoimmune hepatitis: case report and literature review. Case Rep Gastroenterol 5: 553-557, 2011.
14. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101: 15718-15723, 2004.
15. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 21: 702-707, 2005.
16. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 48: 670-678, 2008.
17. Baier JL, Mattner J. Mechanisms of autoimmune liver disease. Discov Med 18: 255-263, 2014.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).